Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Etrasimod for Induction and Maintenance Therapy in Moderately to Severely Active Crohn's Disease
2020-004775-40Phase 2Active
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in Crohn's disease, sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Primary efficacy and safety endpoint (Phase 2b). Started Feb 2021; status: active.
02
Drugs
etrasimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-004775-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004775-40.